Amyotrophic Lateral Sclerosis and Oral Health by Shah, Aakash et al.
ISSN: 2456-7108 
Volume 3, Issue 1, pp. 13-19, January 2018 
 
 
   
 
Copyright © 2017. The Author(s). Published by AIJR Publisher (India). 
This is an open access article under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) 
end user license. 
G R A D U A T E  R E V I E W  A R T I C L E  
Amyotrophic Lateral Sclerosis and Oral Health 
Aakash Shah*, Purvesh Shah, Santosh Kumar Goje, Romil Shah, Bhumi Modi 
Department of Orthodontics and Dentofacial Orthopedics, K.M. Shah Dental College and Hospital,  
Vadodara, Gujarat, India 
 
1 Introduction 
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a degenerative, fatal 
neuromuscular disease. Each year in the United States 5600 people are newly diagnosed.  There is no known 
cure.  From date of diagnosis typical life expectancy is three to five years. During that time, the patient 
steadily deteriorates from a functional state into a completely paralyzed, fully dependent lifestyle. 
Pneumonia induced respiratory failure is the leading cause of death [1]. It is speculated that, as their disease 
advances, patients with ALS often find maintaining oral health quickly becomes a challenge. Recent studies 
associate poor oral hygiene and periodontal disease with colonized oropharyngeal respiratory pathogens 
that, when aspirated, may induce pneumonia [2]. Therefore, ALS patients with insufficient oral health and 
to an even higher degree, patients opting for mechanical ventilation are at an increased risk for developing 
life‐threatening pneumonia. Research also supports the hypothesis that, in these susceptible patients, oral 
and dental health education can reduce the incidence of pneumonia [3]. As the disease progresses and oral 
health care responsibilities transition to the caregiver(s) dental hygiene education and instruction become 
pivotal to the patient’s well‐being. 
AB S T R A CT  
Amyotrophic lateral sclerosis (ALS), commonly referred 
to as Lou Gehrig’s disease is a progressive degenerative 
disorder that affects the nervous system, particularly the 
motor neurons. It may affect either spinal or bulbar 
neurons, which classify how symptoms present in the 
individual. Currently, the cause of ALS is unknown, 
although research indicates the possibility of genetic and 
environmental factors affecting its incidence. It is 
important for health care practitioners to understand 
amyotrophic lateral sclerosis to enable them to make 
modifications to patient care as needed. 
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As ALS patients’ motor skills decline the level of difficulty in performing activities of daily living (ADL) 
and obtaining medical care increases. Not only is it an obstacle for the patient but, finances, transportation 
and treatment scheduling also complicate the matter for caregivers. Dental health care and oral hygiene, 
initially maintained by the patient now become the responsibility of the caregiver. Poor oral hygiene and 
periodontal disease have been positively linked with pneumonia, the leading cause of death in ALS patients 
[2]. Studies have also shown a reduction in pneumonia associated with poor oral health when preventative 
oral hygiene procedures are performed [2]. Therefore, it is imperative that the ALS patient, as well as their 
caregivers, understand not only the significance of oral health but are also trained in proper oral hygiene 
protocols.  
2 Significance of the Problem 
There is no current research supporting the necessity of dental/oral health treatment during the progression 
of ALS. Nor is there research that identifies the varying levels of oral health care required by ALS patients 
throughout the course of the disease. As the ALS patients’ motor skills deteriorate, their ability to maintain 
oral health care also declines. Additionally, caregivers may not be aware of the significance of oral health in 
relationship to the specific needs of the patient. Oral hygiene instruction tailored to the various stages of 
the disease is easily disseminated; and the ALS patient’s primary caregiver is in the optimal position to meet 
those needs. Progressive weakening of the muscles utilized for eating, breathing, drinking and swallowing 
creates additional obstacles for the ALS patient. Management of these symptoms may include ventilatory 
support. Non‐invasive bi‐level positive airway pressure devices (or BiPAP®) machines are often 
incorporated at night for respiratory relief. Tracheostomy and direct mechanical ventilation devices are two 
additional treatment options, though seldom chosen by ALS patients [3]. Regardless of the decision, all 
these options have profound effects on the oral cavity and one’s ability to maintain dental health. Because 
the patient’s condition may rapidly change, oral hygiene education needs to be provided to both the patient 
and the caregiver. Obtaining dental care at a dental facility often poses its own set of complications. Not all 
dental practices are equipped to handle ALS patients in all of their variant stages. Patients may have to seek 
care from a different provider or forego dental treatment altogether. While changing health care providers 
can be stressful to any person, to the patient with ALS, this process may prove to be overwhelming and 
negatively influence their decision to seek care. Evaluation of ALS patients’ dental needs is imperative in 
providing optimal patient care. Assessing the patient’s current dental condition and oral health knowledge 
may provide valuable information regarding whether the inclusion of a dental component within ALS 
Association Multidisciplinary Clinics would be beneficial. 
2.1 Operational Definitions 
2.1.1 Activities of Daily Living (ADL) 
Basic personal tasks in caring for oneself daily, for example, dressing, bathing and eating. 
2.1.2 Amyotrophic Lateral Sclerosis (ALS) 
It is a chronic disease which leads to degeneration of nerve cells of the central nervous system. The disorder 
leads to atrophy and muscle weakness. There is no known etiology for it and it is non-curable. 
2.1.3 Upper Motor Neuron 
Found in the motor cortex area of the brain, they send messages to lower motor neurons to control skeletal 
muscle movement. Primarily involved with maintaining muscle tone and initiation of voluntary muscle 
movement. 
2.1.4 Lower Motor Neuron 
Also known as anterior horn cells, they take messages from upper motor neurons to control the muscle 
fibers they innervate. 
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2.1.5 Bi-level Positive Airway Pressure (BiPAP) 
Mechanical ventilation designed to assist patients in moving air both into and out of lungs. 
2.1.6 Mechanical Ventilation 
Machines used to assist or replace spontaneous breathing. 
2.1.7 Invasive 
Artificially supported ventilation provided through a cannula or breathing tube placed directly into patient’s 
trachea. 
2.1.8 Non-invasive 
Ventilatory assistance delivered via a nasal, oral/nasal or full‐face mask designed to replicate patients’ 
normal respiration. 
2.1.9 Ventilator-Associated Pneumonia (VAP) 
Common complication causing significant morbidity and mortality in critically ill patients, broadly defined 
as pneumonia developing more than 48 hours after intubation. 
2.1.10 Durable Medical Equipment (DME) 
Adaptive, reusable medical equipment used to improve patient comfort and/or prolong patient 
independence. Must be medically necessary and prescribed by a physician. 
3 Amyotrophic Lateral Sclerosis (ALS)  
3.1 History 
It was Jean Martin Charcot, a French physician and founder of modern neurology who, in the 1870’s, first 
linked the symptoms of amyotrophic lateral sclerosis to the group of nerves specifically affected by the 
disease [4]. It is believed Charcot employed a housemaid with ALS and was therefore able to systematically 
observe the clinical manifestations of her disease. His meticulous observations and descriptions of the 
disease remain accurate today. Throughout the world the disease is known by different names.  In parts of 
Europe the disease is still known as Maladie de Charcot (Charcot’s disease). In the United States, the disease 
is widely recognized as ALS or Lou Gehrig’s disease; named after New York Yankees baseball legend Lou 
Gehrig, who retired after being diagnosed in 1939.  
3.2 Etiology 
A multitude of theories have postulated the etiology of ALS. However, to date, none have proved 
statistically significant. Charcot first hypothesized a correlation between poliomyelitis and the development 
of ALS. In 1907, Wilson’s theory gained momentum through the early 1900’s until research showed 
mercury and lead, the leading suspects, were capable of producing reversible ALS‐like symptoms. Current 
research leans toward a vast multifactorial approach encompassing genetics, viral, autoimmune and 
neurotoxic hypotheses. [5] 
3.3 Clinical Features 
ALS is a disorder of the motor neurons responsible for contracting the skeletal muscles. In health, lower 
motor neurons, located in the brain stem and spinal cord, innervate the muscle fibers. When a motor neuron 
fiber becomes diseased it can no longer control the muscle it innervates and denervation occurs. 
Consequently, the impaired muscle fibers shrink and the muscle becomes unable to contract. If surrounding 
motor neurons are healthy they can regenerate nerve fibers and take over control from the denervated 
fibers. Despite the overall reduction in the number of motor neurons, as long as this process is maintained, 
muscle strength remains constant. When the rate of denervation exceeds the rate of reinnervation, muscle 
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first symptoms noted. Initial limb (arm or leg) weakness is more common than bulbar onset; which involves 
muscles controlling speech and swallowing. Typical signs of lower motor neuron degeneration include 
muscle weakness, muscle atrophy, muscle cramping, fasciculations, paretic bulbar palsy (dysarthria, 
dysphagia, sialorrhea), hyporeflexia and difficulty swallowing which can lead to life‐threatening aspiration 
issues. Upper motor neurons are located in the brain and brain stem. They carry information from brain 
centers that control the muscles of the body. These neurons synapse with the lower motor neurons which 
transmit information to the muscles. Therefore, in order for motor commands generated in the central 
nervous system to reach the muscles of the body, signals must utilize both the upper and the lower motor 
neurons. Upper motor neuron dysfunction progresses more slowly and reveals itself in symptoms such as 
loss of dexterity, muscle spasticity, hyperreflexia and spastic bulbar palsy. 
The type and degree of motor neuron onset are two of the main characteristics utilized in diagnosing and 
classifying ALS. Another popular basis used in classification is the method of acquisition. Ninety to ninety‐
five percent of patients have the sporadic form of ALS (SALS); ALS with no known familial history. The 
remaining 5‐10% have familial ALS (FALS), with a close relative having the disease. The clinical features 
of the two acquisition types are indistinguishable. In 1998 the El Escorial criteria was developed as the 
standard for classifying ALS patients in clinical research. These criteria are based on clinical evidence of 
lower and upper motor neuron involvement and represent the degree of diagnostic certainty. 
3.4 Diagnosis 
Currently there is no one hundred percent accurate, definitive test to diagnose ALS. Diagnosis is based on 
a myriad of signs, symptoms, neurological and laboratory data while simultaneously eliminating the diverse 
diagnostic alternatives that mimic ALS. The SOD1 genetic mutation represents the only known cause in 
ALS development. However, subsequent studies on American and British FALS patients, have shown that 
the SOD1 genetic mutation only accounts for 20% of inherited ALS [6]-[7]. 
3.5 Treatment 
Predominant treatment consists of a variety of physical therapies and palliative drugs. In 1995, Rilutek® 
(riluzole) became the first FDA approved ALS drug. To date, it remains the only FDA approved ALS drug 
available in the United States. Researchers believe riluzole helps protect the motor neurons from an 
overproduction of glutamate; a substance involved in nervous system function which, in excess, proves 
toxic to the neurons [8]. Clinical trials have demonstrated a modest two to three-month extension in life 
expectancy [8]. Consequently, drug discovery remains a challenge, as pharmaceutical companies are unlikely 
to make a profit from such a small market. Hence, they do not dedicate resources to costly research and 
drug development. Despite these initiatives, today more than 130 years later, ALS remains an incurable 
disease. 
3.6 Primary Cause of Death 
Clinical death is defined as the cessation of the two-primary criteria necessary to sustain life: blood 
circulation and breathing. Most resources available on amyotrophic lateral sclerosis identify the leading 
cause of clinical death as respiratory failure [1], [9]-[11]. The pathological cause of death is diagnosed 
through laboratory analysis of bodily fluids and/or tissues. In the post mortem state this process is known 
as an autopsy. To date, very little literature exists identifying the cause of death in ALS patients through 
post mortem pathological analysis. It is estimated the autopsy rate among ALS patients is approximately 
four percent [9]. Within the body of research that does exist, the primary cause of death in more than 70 
percent of the cases is either broncho‐pneumonia or aspiration pneumonia [1], [9]-[11]. A twenty‐two-year 
study following 100 ALS patients found a major discrepancy between the clinically assessed and 
pathologically determined cause of death [10]. A less than 20% concordance between clinical and 
pathological conclusions, showed clinical assessment not to be a reliable marker of death [10]. 
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4 Correlation Between Oral Health and Respiratory Disease 
Recent literature supports the association between respiratory disease and oral health and confirms the oral 
cavity to be a harbor of infectious respiratory pathogens [2]. In 2001, following a nine-year study of 358 
veterans, dental decay and the presence of cariogenic bacteria and periodontal pathogens were shown to be 
significant aspiration pneumonia risk factors [12]. Another study observed 189 elderly persons over a four-
year period and confirmed an association between pneumonia and decayed teeth. In this study dependence 
on caregivers was also linked to pneumonia [13]. A third study linked higher plaque scores with a previous 
history of respiratory tract infections [14]. Periodontal disease has been moderately associated with 
atherosclerosis, myocardial infarction and cardiovascular disease [15] and the risk of chronic obstructive 
pulmonary disease is also known to be significantly elevated with severe periodontal attachment loss [16]. 
Pneumonia is defined as an inflammatory condition of the lung caused by bacterial, viral, fungal or parasitic 
infections. The risk of pneumonia is, in part, determined by the specific bacteria inhaled and the body’s 
ability to eliminate the bacteria from the airway mucosa. To eliminate aspirated bacteria from the lower 
airway, multiple defense mechanisms must function properly. Poor oral hygiene and the presence of 
periodontal disease may foster oropharyngeal colonization of respiratory pathogens which increase the 
probability of aspiration pneumonia, especially in high‐risk patients [2], [17]. The effectiveness of these 
mechanisms may also be further impaired by a variety of life conditions such as advanced age, residing in a 
nursing home or hospital and debilitated persons [2]. 
5 Mechanical Ventilation and Respiratory Diseases 
In advanced stages of ALS the process breathing, or voluntarily exchanging oxygen and carbon dioxide, 
may become difficult and often results in respiratory distress. Symptoms often include headaches upon 
waking, physical exhaustion, labored breathing, and the inability to cough or speak long sentences. 
Decisions associated with ventilatory assistance become integral in ALS disease management [18]. Options 
include non‐invasive positive pressure ventilation (NIPPV) and invasive ventilation. Both modalities 
demonstrate prolonged survival rates and are believed to improve the patient’s overall quality of life [19]-
[23]. Bilevel positive pressure airway machines, otherwise known as a BiPAP, are considered a non‐ invasive 
form of artificial ventilation. Unlike CPAP, which provides continuous airway pressure, the BiPAP unit 
provides two levels of air pressure, one on inhalation and another on expiration. Variant nasal and facial 
delivery systems are available to assist with oxygen intake and carbon dioxide removal. There are other 
forms of non‐invasive assisted ventilation available. However, in ALS patients, the BiPAP system is most 
prevalent [24]. Noninvasive positive pressure ventilation use in ALS patients has been associated with 
prolonged survival rates [24]. In recent years nocturnal NIPPV use has become the treatment of choice for 
ALS patients suffering chronic respiratory insufficiency. The extent of NIPPV use in amyotrophic lateral 
sclerosis patients has not been widely studied [24]. Approximately three to five percent of ALS patients 
elected to have invasive ventilation [24]. Mechanical ventilatory support is provided via a tracheostomy, a 
surgically created opening in the trachea through which air is forced on an individualized, timed cycle. 
Nosocomial bacterial pneumonia, or ventilator‐associated pneumonia (VAP), is the most common 
infection. VAP is associated with a seven to twenty‐one-fold increase in the incidence of pneumonia and 
accounts for 47% of all ICU patient infections [25]. Another study found nosocomial pneumonia 
prevalence in ICU’s ranged from 10% – 65%, with a thirteen to fifty‐five percent fatality rate [26]. Studies 
conducted in the 1990’s suggest ventilator‐ associated pneumonia is a vital outcome determinant in critically 
ill patients [26]. 
6 Reduction of Respiratory Complications Through Oral Health Care Measures 
Poor oral health can lead to complex medical and dental issues [27]. It has also been positively linked to an 
increased incidence of pneumonia in ventilated, debilitated and other high‐risk patient groups [2], [12]. A 
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respiratory complications through oral hygiene measures. Standardized oral hygiene protocols can 
effectively decrease the colonization of dental bacteria associated with respiratory pathogens that cause 
pneumonia [28]-[33]. Mechanical toothbrushing and chlorhexidine mouthrinses were shown to be the two 
most effective modalities [28]-[33]. A 2009 study found, after implementation of an oral care protocol, a 
46% reduction in ventilator‐associated pneumonia cases during a twelve-month period [27]. Studies 
confirmed these results not only with ICU patients but also in nursing home residents [29]. 
The majority of ALS patients that elect to die home is variant upon geographical region. In Europe it 
approximately 52‐63% of patients die at home in contrast to 85% electing to die at home within the United 
States [34]-[36]. As the disease progressed, the caregiver’s burden becomes enormous; exponentially more 
so when mechanical ventilation is involved. Many caregivers resort to hospice or hire skilled health care 
workers for assistance with the constant care that is required. 
7 Conclusions 
Amyotrophic lateral sclerosis, a degenerative neural disorder, ultimately affects multiple body systems. Its 
poor prognosis and rapid progression lead to quick, visible symptoms. The initial symptoms vary according 
to the type of neural involvement in the individual. All patients afflicted with ALS show signs of dysphagia 
and other oral complications. The dental implications of ALS span both home and professional clinical 
care. As such, it is important for the dental practitioner to have an understanding of the disease and the 
modifications needed to treat patients with ALS. 
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